Power One Resources Corp.(TSXV:PWRO) (“Power One” or the “Company”) is continuing a comprehensive evaluation of historic drill logs, assessment reports, and archived geological datasets, following the compilation of recent data at its wholly owned Pecors Property, located in Ontario's Elliot Lake Uranium Belt. This review highlights bitumen staining and hydrocarbon-related signatures previously documented during historical […]

PHOENIX, Dec. 02, 2025 (GLOBE NEWSWIRE) — AMPS, a healthcare technology solutions company serving self-insured employer groups, payors, healthcare brokers and consultants, and third-party administrators, announced today that its enterprise systems have earned HITRUST e1 Assessment Certification for cybersecurity and information protection. The HITRUST e1 Certification demonstrates that AMPS has met requirements defined by leading

AMPS Achieves HITRUST e1 Certification, Solidifying Commitment to Data Security in Healthcare GlobeNewswire December 02, 2025 PHOENIX, Dec. 02, 2025 (GLOBE NEWSWIRE) — AMPS, a healthcare technology solutions company serving self-insured employer groups, payors, healthcare brokers and consultants, and third-party administrators, announced today that its enterprise systems have earned HITRUST e1 Assessment Certification for cybersecurity

— Eight causes advancing education, health, culture and resilience — Grants fuel long‑term wellbeing and uplift overlooked communities In celebration of Giving Tuesday, Yuhaaviatam of San Manuel Nation (YSMN) announced $450,000 in grants to eight local and Native‑led nonprofits, underscoring the Tribe's commitment to empower communities, elevate voices and build pathways to lasting resilience. The

The Ademi Firm continues to investigate Comerica (NYSE: CMA) for possible breaches of fiduciary duty and other violations of law in its transaction with Fifth Third. https://mma.prnewswire.com/media/2672539/Ademi_Fruchter__Logo.jpg Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to

Keches Law Group announced today that the Massachusetts Superior Court has issued a sweeping judgment, #2284CV00652-BLS2, exceeding $90 million in favor of a union mason who previously won a$26.6 million jury verdictin 2021. The Court found that Peerless Insurance Company, Liberty Mutual Fire Insurance Company, and Ohio Casualty Insurance Company engaged in unfair and deceptive

(NASDAQ:COSM), CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that Chief Executive Officer Greg Siokas has further increased his ownership in the Company through continued share acquisitions during November 2025. Specifically, between 19 November and 28 November 2025,

Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases GlobeNewswire December 02, 2025 CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that Chief Executive Officer Greg Siokas has further increased his ownership in

CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) — Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a pivotal Phase III clinical trial of QTX-2101, an investigational oral arsenic trioxide capsule. The trial will evaluate the efficacy, safety, and pharmacokinetics of QTX-2101, as a potential new treatment for

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL) GlobeNewswire December 02, 2025 CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) — Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a pivotal Phase III clinical trial of QTX-2101, an investigational oral arsenic